The purpose of this study is to find out whether an investigational product, called LN-145, is safe and effective in the treatment of patients with Non-Small-Cell Lung Cancer (NSCLC). LN-145 is created by modifying your own cells and delivering them back in an infusion. This study is being sponsored by Iovance Biotherapeutics.
COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4
United States (Nationwide)
Jared Weiss
LCCC - Clinical Trials
Clinical or Medical
Interventional
Cancer (Lung)
21-0457